Trial Profile

MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies with Q702, a Small Molecular Inhibitor

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adrixetinib (Primary)
Indications Erdheim-Chester disease; Follicular lymphoma; Langerhans cell histiocytosis; Leukaemia; Lymphoma; Mantle-cell lymphoma; Sarcoma; Sinus histiocytosis; T-cell lymphoma; Waldenstrom's macroglobulinaemia
Focus Adverse reactions; Therapeutic Use
Sponsors Mayo Clinic

Most Recent Events

28 Aug 2025 Planned End Date changed from 15 Oct 2030 to 15 Sep 2030.
28 Aug 2025 Planned primary completion date changed from 15 Oct 2030 to 15 Sep 2030.
28 Aug 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com